Amprion News

Amprion Exhibits at MDS International Congress of Parkinson’s Disease and Movement Disorders in Madrid and Presents Scientific Insights On SYNTap® Test at Prion2022 Conference

September 16, 2022

Amprion Announces Research Collaboration With Mayo Clinic To Further Understand Rapidly Progressive Dementia

August 2, 2022

Amprion Awarded NIH Grant For Analytical Validation of SYNTap® Biomarker Test For Neurological Disease

May 10, 2022

SYNTap Biomarker Test helps doctors distinguish Parkinson’s from Parkinsonism in early stages

April 6, 2022

Amprion Announces Commercial Rollout of the SYNTap Test at the AAN Annual Meeting and the Formation of Clinical Advisory Board

April 1, 2022

New Insights on Alzheimer’s and What it means for Personalized Medicine

January 19, 2022

Amprion Awarded CAP Accreditation

October 27, 2021

Launch of SYNTap™ Test

October 5, 2021

US FDA Awards Amprion Breakthrough Device Designation

May 22, 2019

A pioneer in the science of detecting mis-folded proteins, Amprion advances the diagnosis of brain disorders. Our SYNTap™️ Biomarker Test aids physicians in diagnosing Parkinson’s, Lewy Body Dementia, and Alzheimer’s with Lewy Body variant. We plan to launch more biomarker tests in the future.

Amprion News

Company

Support

Clinical Lab